Literature DB >> 19540929

siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.

Sunit Kumar Singh1, Praveensingh B Hajeri.   

Abstract

RNA interference (RNAi) is a sequence-specific mechanism to control the expression of target genes. This technique has proven potentials both in vivo and in vitro. The main hurdle for using RNAi-based therapy is the effective delivery of RNAi-based drugs to the target cells or tissues in vivo. The aspects of off-target effects, delivery methods, induction of immune response and dose determination for delivery should, however, be considered carefully. If these challenges associated with siRNA can be met, then the potentials of RNAi could be exploited to the full for the development of therapeutic tools and drugs.

Mesh:

Substances:

Year:  2009        PMID: 19540929     DOI: 10.1016/j.drudis.2009.06.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors.

Authors:  Meni Wanunu; Tali Dadosh; Vishva Ray; Jingmin Jin; Larry McReynolds; Marija Drndić
Journal:  Nat Nanotechnol       Date:  2010-10-24       Impact factor: 39.213

Review 2.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

Review 3.  Genomic screening with RNAi: results and challenges.

Authors:  Stephanie Mohr; Chris Bakal; Norbert Perrimon
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

4.  Western blot evaluation of siRNA delivery by pH-responsive peptides.

Authors:  Wanling Liang; A James Mason; Jenny K W Lam
Journal:  Methods Mol Biol       Date:  2013

5.  Chemical synthesis of site-specifically 2'-azido-modified RNA and potential applications for bioconjugation and RNA interference.

Authors:  Michaela Aigner; Markus Hartl; Katja Fauster; Jessica Steger; Klaus Bister; Ronald Micura
Journal:  Chembiochem       Date:  2011-01-03       Impact factor: 3.164

6.  Preclinical development of siRNA therapeutics for AL amyloidosis.

Authors:  B M Hovey; J E Ward; P Soo Hoo; C J O'Hara; L H Connors; D C Seldin
Journal:  Gene Ther       Date:  2011-05-12       Impact factor: 5.250

7.  2'-Azido RNA, a versatile tool for chemical biology: synthesis, X-ray structure, siRNA applications, click labeling.

Authors:  Katja Fauster; Markus Hartl; Tobias Santner; Michaela Aigner; Christoph Kreutz; Klaus Bister; Eric Ennifar; Ronald Micura
Journal:  ACS Chem Biol       Date:  2012-01-24       Impact factor: 5.100

8.  shRNA mediated knockdown of Nav1.7 in rat dorsal root ganglion attenuates pain following burn injury.

Authors:  Weihua Cai; Jing Cao; Xiuhua Ren; Liang Qiao; Xuemei Chen; Ming Li; Weidong Zang
Journal:  BMC Anesthesiol       Date:  2016-08-11       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.